



To the OMX Nordic Exchange Copenhagen
Announcement No. 26-07 / Copenhagen 11 July 2007

TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771

www.topotarget.com

Major Shareholder Announcement

On behalf of Massachusetts Financial Services Investment Management, TopoTarget A/S announces the following:

Pursuant to the Danish Securities Trading Act and Executive Order on Assessment, Notification and Disclosure of Major Holdings in Companies with Shares Listed on a Stock Exchange or Traded in an Authorized Market Place (Executive Order No. 274 of 21 March 2007), this serves as notice of substantial shareholder disclosure for Massachusetts Financial Services Company and its investment advisory subsidiaries ("MFS"), which serve as investment manager for its various mutual funds, institutional account and other advisory clients.

According to announcement No. 25-07 / sent to the OMX Nordic Exchange Copenhagen, 29 June 2007. TopoTarget has increased the total shares rights to 61,304,510; causing MFS and its various subsidiaries to fall below 5% ownership of TopoTarget A/S on 2 July 2007. As of end day, 2 July 2007, MFS on behalf of its various clients¹, held 3,009,074 shares, equivalent to 4.91% of the total issued share capital of TopoTarget A/S (based on 61,304,510 total shares outstanding). Please note that of 4.91% of total shares held by MFS, 2.45% represents shares where MFS has discretionary voting power. Various subsidiary investment advisers of MFS manage the shareholdings, which are set forth below:

MFS International Ltd.:	127,800 Shares	0.21%
MFS International (U.K.) Ltd.:	1,015,200 Shares	1.66%
MFS Investment Management (Lux) S.A.:	1,032,500 Shares	1.68%
MFS Institutional Advisors, Inc.:	853,574 Shares	1.36%

¹ MFS Clients, including the mutual funds and other institutional accounts, are the actual shareholders of the shares discussed herein, where MFS holds investment discretion and, in most cases voting discretion over such shares.

TopoTarget A/S



Major shareholder announcement

For further information, please contact:

Dr. Peter Buhl Jensen
Chief Executive Officer

Telephone +45 39 17 83 41
Mobile +45 21 60 89 22

Background information

About TopoTarget

TopoTarget (OMX – The Nordic Exchange: TOPO) is a biopharmaceutical company, headquartered in Denmark and with subsidiaries in the UK, Germany, Switzerland and the USA, dedicated to finding "Answers for Cancer" and developing improved cancer therapies. TopoTarget is founded and run by clinical cancer specialists and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer. Focus lies on highly predictive cancer models and key cancer targets (including HDAC, NAD+, FasLigand, mTOR, and topoisomerase II inhibitors) and a strong development foundation has been built. TopoTarget has a broad portfolio of small molecule pre-clinical drug candidates and eight drugs are in clinical development, including both novel anti-cancer therapeutics and new cancer indications for existing drugs. Savene™ is TopoTarget's first product on the market. The product is expected to be approved and launched in the US in the second half of 2007. In addition to organic growth, TopoTarget consistently looks for opportunities to strengthen and expand its activities through acquisitions and in-licensing. For more information, please refer to www.topotarget.com.

TopoTarget Safe Harbour Statement

This announcement may contain forward-looking statements, including statements about our expectations of the progression of our preclinical and clinical pipeline including the timing for commencement and completion of clinical trials and with respect to cash burn guidance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. TopoTarget cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: the risk that any one or more of the drug development programs of TopoTarget will not proceed as planned for technical, scientific or commercial reasons or due to patient enrolment issues or based on new information from non-clinical or clinical studies or from other sources; the success of competing products and technologies; technological uncertainty and product development risks; uncertainty of additional funding; TopoTarget's history of incurring losses and the uncertainty of achieving profitability; TopoTarget's stage of development as a biopharmaceutical company; government regulation; patent infringement claims against TopoTarget's products, processes and technologies; the ability to protect TopoTarget's patents and proprietary rights; uncertainties relating to commercialization rights; and product liability expo-sure; We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

